Study Identifies Integrated Stress Response as Target for Antiviral Drug Development Against Zika, HSV, and RSV

A recent study has identified a potential platform for antiviral drug discovery targeting the integrated stress response (ISR), which could be used to combat viruses such as Zika, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). Researchers focused on the ISR, a cellular pathway activated during viral infections, as a promising target for developing broad-spectrum antiviral therapies. The findings suggest that modulating this pathway may inhibit viral replication and provide new treatment options for these diseases.

The study highlights the role of the ISR in regulating cellular responses to stress caused by viral infections. By interfering with this pathway, researchers demonstrated the ability to suppress replication in multiple viruses, including Zika, HSV, and RSV. The research team utilized advanced screening methods to identify compounds capable of modulating the ISR and tested their efficacy in laboratory models. These findings open avenues for further investigation into ISR-targeted therapies as a strategy for addressing viral infections that currently lack effective treatments or vaccines.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 15, 2025

Related posts:

New Guide Details Generic Drug Approval Process, Highlights Potential 12-18 Month Timeline Healthcare Advisory Panel Urges Pharmaceutical Industry to Strengthen Supply Chains Amid Geopolitical Uncertainty Budget Proposal Reduces Funding for Chronic Disease Prevention Programs Under Kennedy Initiative Revolution Medicines Secures $2 Billion from Royalty Pharma to Advance RAS(ON) Cancer Inhibitors

Author

Mark Chiang